TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2022-06, Vol.6 (11), p.3201-3206
Hauptverfasser:	Schimmer, Roman R., Kovtonyuk, Larisa V., Klemm, Nancy, Fullin, Jonas, Stolz, Sebastian M., Mueller, Jan, Caiado, Francisco, Kurppa, Kari J., Ebert, Benjamin L., Manz, Markus G., Boettcher, Steffen
Format:	Artikel
Sprache:	eng
Schlagworte:	Humans Mutation Neoplasms - genetics Proto-Oncogene Proteins c-bcl-2 - genetics Research Letter Tumor Suppressor Protein p53 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	3206
container_issue	11
container_start_page	3201
container_title	Blood advances
container_volume	6
creator	Schimmer, Roman R. Kovtonyuk, Larisa V. Klemm, Nancy Fullin, Jonas Stolz, Sebastian M. Mueller, Jan Caiado, Francisco Kurppa, Kari J. Ebert, Benjamin L. Manz, Markus G. Boettcher, Steffen
description
doi_str_mv	10.1182/bloodadvances.2021005859
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9198927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952922000507</els_id><sourcerecordid>2620077101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-a23c655b33a88ee18330e2adccdb3a7f9489556824526b3cdb7d5b777d31fe533</originalsourceid><addsrcrecordid>eNqFkUtvGyEUhVHVqonS_IWKZTeT8hgG2FRqrL4kS-0iXSMG7thUM-ACtuR_HyynbrPqiivuud-5cBDClNxRqtj7cU7JW3-w0UG5Y4RRQoQS-gW6Zr3knRZcvrzUTF-h21J-EUKoHLjQ7DW64oKwQfXsGvmHH4LjZV9tDSkW7FKcIOMMJZR6csA14e1xlxao2-PcVHGD7QZiLdhGj-9X647hELdhDCdCK_FyhDkFjyOk3WzLUt6gV5OdC9w-nTfo5-dPD6uv3fr7l2-rj-vO9VLXzjLuBiFGzq1SAFRxToBZ75wfuZWT7pUWYlCsF2wYebuVXoxSSs_pBILzG_ThzN3txwW8a1tmO5tdDovNR5NsMM87MWzNJh2MplppJhvg3RMgp997KNUsoTiYZ9vesi-GDYwQKSmhTarOUpdTKRmmiw0l5pSTeZaT-ZtTG33775qXwT-pNMH9WQDtsw4BsikuQMP4kMFV41P4v8sjTIiruA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2620077101</pqid></control><display><type>article</type><title>TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Schimmer, Roman R. ; Kovtonyuk, Larisa V. ; Klemm, Nancy ; Fullin, Jonas ; Stolz, Sebastian M. ; Mueller, Jan ; Caiado, Francisco ; Kurppa, Kari J. ; Ebert, Benjamin L. ; Manz, Markus G. ; Boettcher, Steffen</creator><creatorcontrib>Schimmer, Roman R. ; Kovtonyuk, Larisa V. ; Klemm, Nancy ; Fullin, Jonas ; Stolz, Sebastian M. ; Mueller, Jan ; Caiado, Francisco ; Kurppa, Kari J. ; Ebert, Benjamin L. ; Manz, Markus G. ; Boettcher, Steffen</creatorcontrib><identifier>ISSN: 2473-9529</identifier><identifier>ISSN: 2473-9537</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2021005859</identifier><identifier>PMID: 35026842</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Humans ; Mutation ; Neoplasms - genetics ; Proto-Oncogene Proteins c-bcl-2 - genetics ; Research Letter ; Tumor Suppressor Protein p53 - genetics</subject><ispartof>Blood advances, 2022-06, Vol.6 (11), p.3201-3206</ispartof><rights>2022 The American Society of Hematology</rights><rights>2022 by The American Society of Hematology. Licensed under , permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-a23c655b33a88ee18330e2adccdb3a7f9489556824526b3cdb7d5b777d31fe533</citedby><cites>FETCH-LOGICAL-c479t-a23c655b33a88ee18330e2adccdb3a7f9489556824526b3cdb7d5b777d31fe533</cites><orcidid>0000-0003-0846-8508 ; 0000-0001-8286-2429 ; 0000-0001-9937-0957 ; 0000-0003-0197-5451</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198927/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198927/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35026842$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schimmer, Roman R.</creatorcontrib><creatorcontrib>Kovtonyuk, Larisa V.</creatorcontrib><creatorcontrib>Klemm, Nancy</creatorcontrib><creatorcontrib>Fullin, Jonas</creatorcontrib><creatorcontrib>Stolz, Sebastian M.</creatorcontrib><creatorcontrib>Mueller, Jan</creatorcontrib><creatorcontrib>Caiado, Francisco</creatorcontrib><creatorcontrib>Kurppa, Kari J.</creatorcontrib><creatorcontrib>Ebert, Benjamin L.</creatorcontrib><creatorcontrib>Manz, Markus G.</creatorcontrib><creatorcontrib>Boettcher, Steffen</creatorcontrib><title>TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><subject>Humans</subject><subject>Mutation</subject><subject>Neoplasms - genetics</subject><subject>Proto-Oncogene Proteins c-bcl-2 - genetics</subject><subject>Research Letter</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><issn>2473-9529</issn><issn>2473-9537</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtvGyEUhVHVqonS_IWKZTeT8hgG2FRqrL4kS-0iXSMG7thUM-ACtuR_HyynbrPqiivuud-5cBDClNxRqtj7cU7JW3-w0UG5Y4RRQoQS-gW6Zr3knRZcvrzUTF-h21J-EUKoHLjQ7DW64oKwQfXsGvmHH4LjZV9tDSkW7FKcIOMMJZR6csA14e1xlxao2-PcVHGD7QZiLdhGj-9X647hELdhDCdCK_FyhDkFjyOk3WzLUt6gV5OdC9w-nTfo5-dPD6uv3fr7l2-rj-vO9VLXzjLuBiFGzq1SAFRxToBZ75wfuZWT7pUWYlCsF2wYebuVXoxSSs_pBILzG_ThzN3txwW8a1tmO5tdDovNR5NsMM87MWzNJh2MplppJhvg3RMgp997KNUsoTiYZ9vesi-GDYwQKSmhTarOUpdTKRmmiw0l5pSTeZaT-ZtTG33775qXwT-pNMH9WQDtsw4BsikuQMP4kMFV41P4v8sjTIiruA</recordid><startdate>20220614</startdate><enddate>20220614</enddate><creator>Schimmer, Roman R.</creator><creator>Kovtonyuk, Larisa V.</creator><creator>Klemm, Nancy</creator><creator>Fullin, Jonas</creator><creator>Stolz, Sebastian M.</creator><creator>Mueller, Jan</creator><creator>Caiado, Francisco</creator><creator>Kurppa, Kari J.</creator><creator>Ebert, Benjamin L.</creator><creator>Manz, Markus G.</creator><creator>Boettcher, Steffen</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0846-8508</orcidid><orcidid>https://orcid.org/0000-0001-8286-2429</orcidid><orcidid>https://orcid.org/0000-0001-9937-0957</orcidid><orcidid>https://orcid.org/0000-0003-0197-5451</orcidid></search><sort><creationdate>20220614</creationdate><title>TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms</title><author>Schimmer, Roman R. ; Kovtonyuk, Larisa V. ; Klemm, Nancy ; Fullin, Jonas ; Stolz, Sebastian M. ; Mueller, Jan ; Caiado, Francisco ; Kurppa, Kari J. ; Ebert, Benjamin L. ; Manz, Markus G. ; Boettcher, Steffen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-a23c655b33a88ee18330e2adccdb3a7f9489556824526b3cdb7d5b777d31fe533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Humans</topic><topic>Mutation</topic><topic>Neoplasms - genetics</topic><topic>Proto-Oncogene Proteins c-bcl-2 - genetics</topic><topic>Research Letter</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schimmer, Roman R.</creatorcontrib><creatorcontrib>Kovtonyuk, Larisa V.</creatorcontrib><creatorcontrib>Klemm, Nancy</creatorcontrib><creatorcontrib>Fullin, Jonas</creatorcontrib><creatorcontrib>Stolz, Sebastian M.</creatorcontrib><creatorcontrib>Mueller, Jan</creatorcontrib><creatorcontrib>Caiado, Francisco</creatorcontrib><creatorcontrib>Kurppa, Kari J.</creatorcontrib><creatorcontrib>Ebert, Benjamin L.</creatorcontrib><creatorcontrib>Manz, Markus G.</creatorcontrib><creatorcontrib>Boettcher, Steffen</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schimmer, Roman R.</au><au>Kovtonyuk, Larisa V.</au><au>Klemm, Nancy</au><au>Fullin, Jonas</au><au>Stolz, Sebastian M.</au><au>Mueller, Jan</au><au>Caiado, Francisco</au><au>Kurppa, Kari J.</au><au>Ebert, Benjamin L.</au><au>Manz, Markus G.</au><au>Boettcher, Steffen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2022-06-14</date><risdate>2022</risdate><volume>6</volume><issue>11</issue><spage>3201</spage><epage>3206</epage><pages>3201-3206</pages><issn>2473-9529</issn><issn>2473-9537</issn><eissn>2473-9537</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35026842</pmid><doi>10.1182/bloodadvances.2021005859</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0846-8508</orcidid><orcidid>https://orcid.org/0000-0001-8286-2429</orcidid><orcidid>https://orcid.org/0000-0001-9937-0957</orcidid><orcidid>https://orcid.org/0000-0003-0197-5451</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2473-9529
ispartof	Blood advances, 2022-06, Vol.6 (11), p.3201-3206
issn	2473-9529 2473-9537 2473-9537
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9198927
source	MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects	Humans Mutation Neoplasms - genetics Proto-Oncogene Proteins c-bcl-2 - genetics Research Letter Tumor Suppressor Protein p53 - genetics
title	TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A00%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TP53%20mutations%20confer%20resistance%20to%20hypomethylating%20agents%20and%20BCL-2%20inhibition%20in%20myeloid%20neoplasms&rft.jtitle=Blood%20advances&rft.au=Schimmer,%20Roman%20R.&rft.date=2022-06-14&rft.volume=6&rft.issue=11&rft.spage=3201&rft.epage=3206&rft.pages=3201-3206&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2021005859&rft_dat=%3Cproquest_pubme%3E2620077101%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2620077101&rft_id=info:pmid/35026842&rft_els_id=S2473952922000507&rfr_iscdi=true